Ocera Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Palo Alto CA United States (2005)
Status: Acquired by Mallinckrodt (2013) (2017)

Organization Overview

First Clinical Trial
2006
NCT00321412
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ocera Therapeutics | Ocera Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Ocera Therapeutics (1) Acquired (2)

glucose monohydrate (5 trials)

kremezin (7 trials)

ulimorelin (5 trials)

Drugs in Phase 2 Trials (4)

Key: Ocera Therapeutics (3) Acquired (1)

cellulose (2 trials)

lactulose (cephulac) (1 trial)

ornithine phenylacetate (4 trials)

tzp-102 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Emergencies (Phase 2)

Esophagitis, Peptic (Phase 2)

Fibrosis (Phase 2)

Fistula (Phase 3)

Gastroesophageal Reflux (Phase 2)

Hepatic Encephalopathy (Phase 2)

Hepatic Insufficiency (Phase 2)

Hyperammonemia (Phase 2)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Intestinal Fistula (Phase 3)

Irritable Bowel Syndrome (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Failure (Phase 2)

Liver Failure, Acute (Phase 2)

Pouchitis (Phase 2)

Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 7